A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a global leader in digital health and cloud-connected medical devices. We design innovative solutions to treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. Our comprehensive residential care software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, our products improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems. Following our formation in 1989, we commercialized a continuous positive airway pressure, or CPAP, treatment for obstructive sleep apnea, or OSA, which was the first successful non-invasive treatment for OSA.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 5.4B | 5.1B | 4.7B | 4.2B | 3.6B | 3.2B |
| Net Income | 1.5B | 1.4B | 1.0B | 898M | 779M | 475M |
| EPS | $10.11 | $9.51 | $6.92 | $6.09 | $5.30 | $3.24 |
| Free Cash Flow | 1.8B | 1.7B | 1.3B | 574M | 216M | 634M |
| ROIC | 35.8% | 30.2% | 20.9% | 18.0% | 22.6% | 16.8% |
| Gross Margin | 60.9% | 59.4% | 56.7% | 55.8% | 56.6% | 57.5% |
| Debt/Equity | 0.11 | 0.11 | 0.15 | 0.35 | 0.23 | 0.23 |
| Dividends/Share | $2.27 | $2.12 | $1.92 | $1.76 | $1.68 | $1.56 |
| Operating Income | 1.8B | 1.7B | 1.3B | 1.1B | 1.0B | 904M |
| Operating Margin | 33.7% | 32.7% | 28.2% | 26.8% | 28.0% | 28.3% |
| ROE | 23.5% | 25.9% | 21.0% | 21.7% | 23.2% | 16.4% |
| Shares Outstanding | 146M | 147M | 148M | 147M | 147M | 146M |
RESMED INC passes 7 of 9 quality checks, indicating strong fundamentals.
RESMED INC trades at 2.5x trailing earnings, compared to its 15-year median P/E of 3.7x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 2.0x vs a median of 3.4x. The company's 5-year average ROIC is 21.7% with a gross margin of 57.2%. Total shareholder yield (dividends + buybacks) is 22.9%. At current prices, the estimated annualized return to fair value is +19.5%.
RESMED INC (RSMDF) has a current P/E ratio of 2.5, compared to its historical median P/E of 3.7. The stock is currently considered Fair based on its historical valuation range.
RESMED INC (RSMDF) has a 5-year average return on invested capital (ROIC) of 21.7%. This indicates strong capital allocation and a potential competitive advantage.
RESMED INC (RSMDF) has a market capitalization of $3.6B. It is classified as a mid-cap stock.
Yes, RESMED INC (RSMDF) pays a dividend with a trailing twelve-month yield of 9.12%. The company also returns capital through share buybacks, with a buyback yield of 13.79%.
Based on historical P/E analysis, RESMED INC (RSMDF) appears fair. The current P/E of 2.5 is 34% below its historical median of 3.7. The estimated fair value CAGR (P/E method) is 22.2%.
RESMED INC (RSMDF) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
RESMED INC (RSMDF) reported annual revenue of $5.1 billion in its most recent fiscal year, based on SEC EDGAR filings.
RESMED INC (RSMDF) has a net profit margin of 27.2%. This is a strong margin indicating high profitability.
RESMED INC (RSMDF) generated $1.7 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
RESMED INC (RSMDF) has a debt-to-equity ratio of 0.11. This indicates a conservatively financed balance sheet.
RESMED INC (RSMDF) reported earnings per share (EPS) of $9.51 in its most recent fiscal year.
RESMED INC (RSMDF) has a return on equity (ROE) of 25.9%. This indicates the company generates strong returns for shareholders.
RESMED INC (RSMDF) has a 5-year average gross margin of 57.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for RESMED INC (RSMDF), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
RESMED INC (RSMDF) has a book value per share of $40.52, based on its most recent annual SEC filing.